Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share guidance for the company’s 2nd quarter financial numbers that is heading to record revenue for the 6th straight quarter. The company saying Q2-23 revenues to exceed 13.5 million dollars while adjusted EBITDA loss will decrease below 2.0 million as the company heads to profitability. Saviuk telling Proactive the number continues to be driven by Asthma medications ENERZAIR and ATECTURA which saw quarterly revenues grow 270% over this time last year. In fact the total number of prescribing physicians also grew and is now expected to exceeds 2,000.
Valeo Pharma Q2 results showing same form as Q1 with guidance showing record setting Revenue
